Grant of options
Fusion Antibodies plc has granted 2,910,000 share options to executive directors and employees under its share option scheme, with an exercise price of 10.30 pence per option, reflecting the closing mid-market price on July 17, 2026. These options will vest equally over three years and can be exercised for ten years. Specifically, the CEO received 600,000 options and the CSO received 400,000 options. Following this grant, the company has a total of 6,086,600 options outstanding, representing 4.86% of its issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company has granted 2,910,000 options (the "Options") over ordinary shares of 4 pence each in the Company ("Ordinary Shares") to certain Executive Directors and employees of the Company. The Options were granted pursuant to the Fusion Antibodies EMI and Unapproved Employee Share Option Scheme (the "Scheme"), adopted by the Company on 11 December 2017.
The Options have an exercise price of 10.30 pence per Option, being the closing mid-market price of an Ordinary Share on 17 July 2026, the business day prior to the date of grant. The Options will vest equally over a three-year period, with one third of the Options vesting on each anniversary following the grant date and subject to continuing employment only. Once vested, the Options can be exercised for a period of ten years from the grant date.
1,000,000 of the Options have been granted to the following Executive Directors of the Company:
| Name | Number of Options granted | Existing options over Ordinary Shares held | Total Options over Ordinary Shares held following grant |
|---|---|---|---|
| Adrian Kinkaid, CEO | 600,000 | 900,000 | 1,500,000 |
| Richard Buick, CSO | 400,000 | 680,000 | 1,080,000 |
Following the grant of the Options, the Company has options in issue over a total of 6,086,600 Ordinary Shares, representing 4.86 per cent. of the Company's issued share capital.
| 2 | Reason for the notification | |
| a) | Position/status | See 1(a) |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Fusion Antibodies plc |
| b) | LEI | 213800KBAYRC9VOQ9V39 |
| a) | Description of the financial instrument, type of instrument Identification code | Options over ordinary shares of 4p each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
| b) | Nature of the transaction | Grant of options over ordinary shares |
| c) | Price(s) and volume(s) | Name Price(s) Volume(s) Adrian Kinkaid 10.30p 600,000 Richard Buick 10.30p 400,000 |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 July 2026 |
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.